Diagnosing and managing gastroparesis - where are we now?

Caroline G. Olson,Brian E. Lacy
DOI: https://doi.org/10.1080/17474124.2024.2431248
2024-12-10
Expert Review of Gastroenterology & Hepatology
Abstract:KEYWORDS: Gastroparesis is a common sensorimotor disorder of the upper gastrointestinal (GI) tract that affects 2–5 million adult Americans [ Citation 1 ]. Gastroparesis (GP) is defined by symptoms thought to represent delayed gastric emptying (although the importance of this has been questioned) in the setting of a normal upper endoscopy and an objective delay in gastric emptying (criteria vary, but some guidelines note that normal should be more than 90% emptied at 4 hours) [ Citation 2 ]. Chronic GP symptoms of nausea, vomiting, early satiety, and abdominal pain have a significant negative economic impact on the health care system and reduce patients' health-related quality of life [ Citation 3 , Citation 4 ]. Diabetes is the most common etiology (17–57%); the majority of these patients are type 2 diabetics (52%). Idiopathic GP accounts for approximately 11% of all cases [ Citation 1 , Citation 4 ]. Gastroparesis treatments frequently center on accelerating gastric emptying, although most studies demonstrate that this strategy does not improve global GP symptoms [ Citation 5 , Citation 6 ]. These results emphasize that GP is not simply a muscular disorder of the stomach characterized by delayed emptying but rather a more complicated disorder involving the brain-gut axis [ Citation 7 ]. This editorial will address some of the controversial issues of GP and highlight potential novel therapeutic pathways.
gastroenterology & hepatology
What problem does this paper attempt to address?